Literature DB >> 12487826

Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS.

Nia D Banks1, Nicole Kinsey, Janice Clements, James E K Hildreth.   

Abstract

Although several in vitro lines of evidence support the potential power of antibody-dependent cell-mediated cytotoxicity (ADCC) in controlling HIV infection, the role of ADCC in the pathogenesis of HIV infection in vivo remains uncertain. There are few studies to date that longitudinally determine the plasma ADCC activity in HIV-infected subjects. We sought to establish an SIV/macaque model to perform such a longitudinal study. In the rhesus macaque cohort studied here, three of five macaques (designated Group 1) maintained higher plasma ADCC activity for at least 1 year after inoculation with SIV/17E-Br. The ADCC activity of the two remaining macaques (Group 2) fell 12 weeks after inoculation. There were also differences in longitudinal measurements of anti-SIV envelope IgG titers and CD4 counts. Group 1 macaques maintained higher antienvelope IgG titers and higher CD4(+) T cell numbers as late as 60 weeks postinoculation, while Group 2 macaques had significantly lower titers at 1 year postinoculation and lower CD4(+) T cell counts by 30 weeks postinoculation. Our study shows a correlation between humoral response, ADCC activity, and disease progression (as measured by CD4(+) T cell counts). In these animals, ADCC activity is associated with delayed progression to AIDS. Further studies are underway to determine if ADCC is a protective immune response in SIV infection or if ADCC is a marker of intact cellular and humoral immune responses.

Entities:  

Mesh:

Year:  2002        PMID: 12487826     DOI: 10.1089/08892220260387940

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  68 in total

1.  Activation of the FcgammaReceptorIIIa on human natural killer cells leads to increased expression of functional interleukin-21 receptor.

Authors:  Elizabeth L McMichael; Nicholas B Courtney; Megan C Duggan; Robert Wesolowski; Dionisia Quiroga; Sri Vidya Kondadasula; Lakhvir S Atwal; Neela Bhave; Eric Luedke; Alena Cristina Jaime-Ramirez; Amanda R Campbell; Xiaokui Mo; John C Byrd; William E Carson Iii
Journal:  Oncoimmunology       Date:  2017-05-02       Impact factor: 8.110

Review 2.  The Antibody Response against HIV-1.

Authors:  Julie Overbaugh; Lynn Morris
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

3.  HIV-1 virus-like particles produced by stably transfected Drosophila S2 cells: a desirable vaccine component.

Authors:  Lifei Yang; Yufeng Song; Xiaomin Li; Xiaoxing Huang; Jingjing Liu; Heng Ding; Ping Zhu; Paul Zhou
Journal:  J Virol       Date:  2012-05-02       Impact factor: 5.103

4.  Divergent antibody subclass and specificity profiles but not protective HLA-B alleles are associated with variable antibody effector function among HIV-1 controllers.

Authors:  Jennifer I Lai; Anna F Licht; Anne-Sophie Dugast; Todd Suscovich; Ickwon Choi; Chris Bailey-Kellogg; Galit Alter; Margaret E Ackerman
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

5.  Phenotypical and functional profiles of natural killer cells exhibiting matrix metalloproteinase-mediated CD16 cleavage after anti-HIV antibody-dependent activation.

Authors:  C-C Tang; G Isitman; J Bruneau; C Tremblay; N F Bernard; S J Kent; M S Parsons
Journal:  Clin Exp Immunol       Date:  2015-06-07       Impact factor: 4.330

6.  Differential Effect of Mucosal NKp44+ Innate Lymphoid Cells and Δγ Cells on Simian Immunodeficiency Virus Infection Outcome in Rhesus Macaques.

Authors:  Mohammad Arif Rahman; Eun-Ju Ko; Gospel Enyindah-Asonye; Sabrina Helmold Hait; Christopher Hogge; Ruth Hunegnaw; David J Venzon; Tanya Hoang; Marjorie Robert-Guroff
Journal:  J Immunol       Date:  2019-09-25       Impact factor: 5.422

7.  HIV-1 Env- and Vpu-Specific Antibody-Dependent Cellular Cytotoxicity Responses Associated with Elite Control of HIV.

Authors:  Vijaya Madhavi; Bruce D Wines; Janaki Amin; Sean Emery; Ester Lopez; Anthony Kelleher; Rob J Center; P Mark Hogarth; Amy W Chung; Stephen J Kent; Ivan Stratov
Journal:  J Virol       Date:  2017-08-24       Impact factor: 5.103

8.  Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC.

Authors:  Karen V Kibler; Benedikt Asbach; Beatriz Perdiguero; Juan García-Arriaza; Nicole L Yates; Robert Parks; Sherry Stanfield-Oakley; Guido Ferrari; David C Montefiori; Georgia D Tomaras; Mario Roederer; Kathryn E Foulds; Donald N Forthal; Michael S Seaman; Steve Self; Raphael Gottardo; Sanjay Phogat; James Tartaglia; Susan Barnett; Anthony D Cristillo; Deborah Weiss; Lindsey Galmin; Song Ding; Jonathan L Heeney; Mariano Esteban; Ralf Wagner; Giuseppe Pantaleo; Bertram L Jacobs
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

9.  Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge.

Authors:  N A Doria-Rose; C Ohlen; P Polacino; C C Pierce; M T Hensel; L Kuller; T Mulvania; D Anderson; P D Greenberg; S-L Hu; N L Haigwood
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

10.  Role of complement and antibodies in controlling infection with pathogenic simian immunodeficiency virus (SIV) in macaques vaccinated with replication-deficient viral vectors.

Authors:  Barbara Falkensammer; Barbara Rubner; Alexander Hiltgartner; Doris Wilflingseder; Christiane Stahl Hennig; Seraphin Kuate; Klaus Uberla; Stephen Norley; Alexander Strasak; Paul Racz; Heribert Stoiber
Journal:  Retrovirology       Date:  2009-06-21       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.